Why is Marksans Pharma falling/rising?

As of 22-Aug, Marksans Pharma Ltd is currently priced at 179.80, reflecting a decline of 1.25, or 0.69%. The stock has been underperforming, having lost 2.52% over the last three days and trading below all key moving averages. Additionally, the stock's delivery volume has decreased significantly, falling by 39.47% against its five-day average. Over the past month, Marksans Pharma has experienced a substantial decline of 25.72%, while its year-to-date performance shows a drop of 39.31%. Despite high management efficiency indicated by a 17.66% return on equity and low debt levels, the company has faced challenges, including poor long-term growth and negative results reported in June 2025.
In the broader market context, the stock's short-term performance has been slightly better than the benchmark Sensex, which gained 0.88% over the past week compared to Marksans Pharma's 0.84% increase. However, the stock has significantly underperformed over longer periods, with a year-over-year decline of 21.84% against the Sensex's modest gain of 0.31%. This underperformance is compounded by the company's recent financial struggles, including a low operating profit margin and an expensive valuation relative to its peers, which have contributed to a lack of investor confidence and declining participation in trading.